$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
多吉美使分化型甲状腺癌死亡的风险41%
2025-10-19 11:44:20
Check Details
乐伐替尼和索拉非尼治疗难治性甲状腺癌的新方法
2025-10-19 11:44:20
Check Details
乐伐替尼等酪氨酸激酶抑制剂治疗碘难治性晚期甲状腺癌
2025-10-19 11:44:20
Check Details
乐伐替尼等酪氨酸激酶抑制剂治疗碘难治性晚期甲状腺癌(二)
2025-10-19 11:44:20
Check Details
乐伐替尼等酪氨酸激酶抑制剂治疗碘难治性晚期甲状腺癌(三)
2025-10-19 11:44:20
Check Details
乐伐替尼在碘难治性甲状腺癌中的应用——瑞士回顾性分析
2025-10-19 11:44:20
Check Details
乐伐替尼治疗碘难治性甲状腺癌:SELECT研究数据更新
2025-10-19 11:44:20
Check Details
索拉非尼治疗碘难治性分化型甲状腺癌:3期试验
2025-10-19 11:44:20
Check Details
乐伐替尼等酪氨酸激酶抑制剂治疗碘难治性晚期甲状腺癌(四)
2025-10-19 11:44:20
Check Details
乐伐替尼获批治疗分化型甲状腺癌
2025-10-19 11:44:20
Check Details
乐伐替尼治疗甲状腺癌疗效明显
2025-10-19 11:44:20
Check Details
乐伐替尼晚期实体瘤I期剂量递增研究
2025-10-19 11:44:20
Check Details
1
2
...
2437
2438
2439
2440
2441
2442
2443
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
2
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
3
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
4
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
5
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
6
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
7
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
8
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
9
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
10
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
11
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
12
Vemurafenib (Zelboraf) Complete Medication Guide